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Pancreatic cancer is a leading cause of cancer-
related death, largely due to metastatic dissemina-
tion. We investigated pancreatic cancer progression
by utilizing a mathematical framework of metastasis
formation together with comprehensive data of 228
patients, 101 of whom had autopsies. We found
that pancreatic cancer growth is initially exponential.
After estimating the rates of pancreatic cancer
growth and dissemination, we determined that
patients likely harbor metastases at diagnosis and
predicted the number and size distribution of metas-
tases as well as patient survival. These findings were
validated in an independent database. Finally, we
analyzed the effects of different treatment modali-
ties, finding that therapies that efficiently reduce
the growth rate of cells earlier in the course of treat-
ment appear to be superior to upfront tumor resec-
tion. These predictions can be validated in the clinic.
Our interdisciplinary approach provides insights into
the dynamics of pancreatic cancer metastasis and
identifies optimum therapeutic interventions.
INTRODUCTION
Pancreatic cancer is the fourth-leading cause of cancer death
and one of the most aggressive malignancies in humans, with
a five-year relative survival rate of only 5% (Jemal et al., 2010).
Pancreatic cancer often develops without early symptoms, and
therefore most patients are diagnosed with metastatic disease.
Treatment options including surgery, radiation, and chemo-
therapy can prolong survival and/or relieve symptoms in many
patients, but rarely lead to a cure (Hidalgo, 2010; Stathis and
Moore, 2010). Until recently, it was unknown if the poor survival362 Cell 148, 362–375, January 20, 2012 ª2012 Elsevier Inc.of pancreatic cancer patients was due to a delay in diagnosis or
to early metastatic dissemination during the clonal evolution of
pancreatic cancer. However, by applying high-throughput
genetic analyses to paired primary and metastatic pancreatic
cancer tissues, recent findings indicate that up to seven years
are required for the development of metastatic subclones within
a primary carcinoma after it has formed, and an additional
2–3 years for these clones to disseminate and cause patient
death. These findings support the notion that metastasis is a
late event in the clonal evolution of this disease (Campbell
et al., 2010; Yachida et al., 2010). In this regard, the growth
dynamics of pancreatic cancer follows a linear progression
paradigm similar to that described for other tumor types, and
thus is a useful model system for understanding the dynamics
of metastasis formation in general.
The genetic features of pancreatic cancer have been
explored in detail and indicate that telomeric shortening and
activating mutations in KRAS are among the earliest and
most pervasive alterations in pancreatic carcinogenesis (Hru-
ban et al., 2000; Iacobuzio-Donahue, 2011; van Heek et al.,
2002). These alterations are followed by inactivating mutations
in the CDKN2A tumor suppressor gene in the mid-stage, and in
the TP53 and SMAD4 tumor suppressor genes in the late stage
of carcinogenesis (Iacobuzio-Donahue, 2011). Mutations in
a variety of other genes such as BRCA2, MLL3, TGFBR1/II
and MKK4 may also occur, albeit at a much lower frequency
(Iacobuzio-Donahue, 2011; Jones et al., 2008). Evaluation of
the temporal sequence of these alterations further indicates
that the majority, if not all, can be classified as founder muta-
tions, i.e., those mutations present in the clonal population of
cells within an intraductal precursor lesion that founded the
infiltrating carcinoma (Yachida et al., 2010). Indeed, the vast
majority of deleterious mutations and rearrangements in
pancreatic cancer are now known to occur during intraductal
carcinogenesis (Campbell et al., 2010; Stephens et al., 2011;
Yachida et al., 2010). While less well understood, epigenetic
alterations may also occur during carcinogenesis, leading to
Table 1. Summary of the Patient Cohorts
Autopsy
Cohort
Adjuvant
Cohort
Total number of
patients
101 127
Age* 64 (55-71) 61 (56-68)
Resected 26 (26%) 127 (100%)
Received adjuvant
therapy
Yes 18 (18%) 127 (100%)
No 12 (12%) 0 (0%)
N/A 67 (67%) 0 (0%)
Unknown 4 (4%) 0 (0%)
Received
neoadjuvant therapy
Yes 2 (2%) 0 (0%)
No 30 (30%) 127 (100%)
N/A 65 (65%) 0 (0%)
Unknown 1 (1%) 0 (0%)
Node-positive Unknown 106 (85%)
Margin-positive Unknown 50 (39%)
Stage I-III 70 (69%) 127 (100%)
Stage IV 31 (31%) 0 (0%)
Tumor size at
diagnosis*
3.7 (2.8-4.2) 3 (2.5-4)
Progression-free
survival*
8.4 (4.6 - 17.7) 12.8 (8.4 - 25.4)
Survival* 11.4 (6.1 - 24.4) 21.0 (13.2-46.4)
See also Table S1. Asterisk indicates that values are shown as median
(first and third quartiles).changes in gene expression of a variety of biomarkers (Sato
and Goggins, 2006).
Beyond carcinogenesis, the molecular mechanisms that
promote the metastatic spread of pancreatic cancer are less
clear. The fact that the vast majority of disseminated pancreatic
cancer cells do not form metastases (Nguyen et al., 2009), and
that a subset of patients have no observable pancreatic metas-
tases post-mortem despite similar clinicopathologic features as
patients who do develop metastatic failure (Iacobuzio-Donahue
et al., 2009), indicates that thedevelopment ofmetastatic disease
requires the acquisition of one or more (epi)genetic events that
may promote survival of disseminated cells within the circulation
and/or target organ sites (Cameron et al., 2000; Luzzi et al., 1998;
Nguyen et al., 2009; Nguyen and Massague´, 2007; Polyak and
Weinberg, 2009; Saha et al., 2001; Valastyan et al., 2009).
Whether this (epi)genetic event occurs during intraductal carci-
nogenesis or during clonal evolution beyond formation of the
carcinoma is uncertain. However, a studyof thepatterns of failure
in patientswith pancreatic cancer indicated that genetic inactiva-
tion of SMAD4 during carcinogenesis, and hence dysregulation
of canonical TGFß signaling, is highly correlatedwith subsequent
distant metastatic failure (Iacobuzio-Donahue et al., 2009). This
finding suggests that loss of SMAD4 during pancreatic carcino-
genesis represents a major and perhaps initial pro-metastatic
event for this tumor type, upon which subsequent events are
superimposed (Iacobuzio-Donahue et al., 2009).In addition to studies addressing the mechanisms by which
pancreatic cancers gain metastatic ability, there is the need to
understand the growth dynamics of pancreatic cancer and its
metastases in association with systemic treatments. This is crit-
ical to know because, until early detection of pancreatic cancer
becomes routine, most patients will likely continue to be diag-
nosed with advanced disease (Hidalgo, 2010; Stathis and
Moore, 2010). For this reason, high quality datasets derived
from rapid autopsy participants allow an unprecedented docu-
mentation of metastatic burden from the time of diagnosis to
death (Embuscado et al., 2005; Liu et al., 2009; Shah et al.,
2004; Yachida et al., 2010). Here we utilize one of these highly
unique patient datasets derived from a rapid autopsy program
for patientswith pancreatic cancer, together with amathematical
framework of pancreatic metastasis development, to under-
stand the growth dynamics of cancer metastasis in the setting
of commonly used anti-cancer therapies. This model is subse-
quently validated using a uniform cohort of patients who under-
went curative resection of their pancreatic cancer followed by
adjuvant chemotherapy and radiation therapy. Our approach is
then used to identify optimum therapeutic interventions, which
can be tested in the clinic. This work is part of an ongoing effort
to analyze cancermetastases usingmathematical and computa-
tional techniques (Andasari et al., 2011; Chauviere et al., 2010;
Dingli et al., 2007; Jadhav et al., 2007; Klein and Holzel, 2006;
Michor et al., 2006; Quaranta et al., 2008; Sherratt, 2001) and
provides new insight into the complexity of metastatic dissemi-
nation as well as suggests optimal treatment strategies for
patients diagnosed with this devastating disease.
RESULTS
Tumor Size and Metastatic Burden of 228 Pancreatic
Cancer Patients
We utilized two independent databases for a combined number
of 228 pancreatic cancer patients. The first database contains
information on 101 pancreatic cancer patients who consented
for autopsy in association with the Gastrointestinal Cancer Rapid
Medical Donation Program (GICRMDP) at Johns Hopkins and
died between October 2006 and February 2011 (Iacobuzio-
Donahue et al., 2009; van Heek et al., 2002); this database
is referred to the ‘‘autopsy cohort’’ (Table 1 and Table S1, avail-
able online). Dates of diagnoses ranged from May, 1995 to
November, 2010. For each patient, data on the primary tumor
size and metastatic burden at diagnosis and at autopsy were re-
corded (Figure 1A). In addition, at least one intermediate evalua-
tion of the primary tumor, local and distant recurrence as well as
metastases was available. Many patients had numerous meta-
static tumors at the time of autopsy, and the metastatic burden
was categorized into one of three classes: <10 metastases,
10–99 metastases, and >100 metastases.
Themedian age at diagnosis of these 101 patients was 64 (first
and third quartiles: 55 and 71). The median size of the primary
tumor was 3.7 cm (first and third quartiles: 2.8 and 4.2). Sixty-
one patients (60%) had no evidence of metastases at diagnosis.
The median size of the largest metastatic tumor in patients with
metastatic disease at diagnosis was 2 cm (first and third quar-
tiles: 1.2 and 3.0). The primary tumor was surgically removedCell 148, 362–375, January 20, 2012 ª2012 Elsevier Inc. 363
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Figure 1. A Mathematical Framework of Pancreatic Cancer Progression Allows the Prediction of Growth and Dissemination Kinetics
(A) Computed tomography (axial view) of one representative patient at initial diagnosis, one intermediate time point five months later, and then again at 7 months
after diagnosis, which was also one week before death. In each image the primary pancreatic cancer is indicated in dashed yellow outlines and the liver
metastases by dashed red outlines.
(B) The mathematical framework. The model considers three cell types: type-0 cells, which have not yet evolved the ability to metastasize, reside in the primary
tumor where they proliferate and die at rates r and d. They give rise to type-1 cells at rate u per cell division; these cells have evolved the ability to metastasize but
still reside in the primary tumor, where they proliferate and die at rates a1 and b1, respectively, and disseminate to a new metastatic site at rate q per time unit.
Once disseminated, cells are called type-2 cells and proliferate and die at rates a2 and b2, respectively. This mathematical framework can be used to determine
quantities such as the risk of metastatic disease at diagnosis and the expected number of metastasized cells at death.
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in 26 patients (26%). At autopsy, nine patients (9%) did not have
a detectable primary tumor and for those who had a detectable
primary tumor at autopsy, the median size was 4.8 cm (first and
third quartiles: 4 and 6). Fourteen patients (14%) had no meta-
static deposits at autopsy, 19 (19%) had <10, 30 (30%) had
10–99, and 38 (37%) had >100metastatic tumors. The diameters
of largest metastases ranged from 0.5 to 14 cm with a median of
2.7 cm (first and third quartiles: 2 and 4). Themedian survival was
significantly different (p value < 0.0001) between those who
underwent surgical resection of the primary tumor (24.5, first
and third quartiles: 14.8 and 34.7 months, n = 26) and those
who did not (8.4, first and third quartiles: 4.5 and 16.8 months,
n = 75).
Using the 47 patients who had at least one intermediate time
point between diagnosis and autopsy, we compared the fit of
linear and exponential growth models of primary and metastatic
tumors. The exponential model had a better fit than the linear
model in 71% of the cases, with a median R2 of 0.63 (0.24–
0.88). Other growth models such as a logistic model did not
converge for most patients, due to sparsity of the data.
The second database from Johns Hopkins Hospital contained
information on 127 pancreatic cancer patients who received
curative surgical resection between January, 1994 and
December, 2008; this database is referred to as the ‘‘adjuvant
cohort’’ (Table 1). The median age was 61 (first and third quar-
tiles: 56–68) and 51 (41%) of the patients were women. At the
time of analysis, 89 (71%) patients were dead. The size of the
primary tumor at the time of surgical resection ranged from
0.7 cm–9.5 cm with a median of 3 cm (first and third quartiles:
2.5 and 4). Fifty (39%) of the primary tumors were poorly differ-
entiated and seventy-seven (61%) had margin-negative resec-
tions. Fifty (39%) of the tumors had vascular invasion and 98
(78%) had perineural invasion. All patients received adjuvant
chemotherapy and radiation therapy and had complete follow-
up and available data on patterns of failure. A majority (84%)
received 5-FU based chemoradiation while gemcitabine (16%)
was also used as the backbone for chemoradiation. The median
follow-up was 78 months and median overall survival was
21.0 months. Thirty-one developed a local recurrence in the
tumor bed while 64 developed distant metastases as a site of
first failure. Patterns of failure (local, regional, and distant) and
burden (quantitative) of disease were recorded until death.
A Mathematical Framework to Investigate Growth
and Dissemination
We designed a mathematical model of pancreatic cancer
progression and dissemination to investigate the dynamics of
cancer cell growth and metastasis, the survival of patients, and
optimum intervention strategies. The model considers exponen-
tial expansion of pancreatic cancer cells starting from a single
cell that has not yet evolved the ability to metastasize; this cell(C and D) Estimated mutation and dissemination rates allow the prediction of th
between the data and the results of the mathematical model; we used patient dat
then calculated the geometric mean of the two values for each point. Darker color
detailed analysis of the data shown in panel (C).
(E) The panel shows the probability of metastasis at diagnosis (red curve) and the
potential to metastasize (blue curve). Parameters are u = 6.31 $ 10-5, q = 6.31 $might, however, already have accumulated all necessary (epi)
genetic alterations for proliferation. We chose an exponential
model over other functional forms since the exponential model
provided a better fit to the data as compared to a linear model
(R2 of 0.63, see above) and does not require as many data points
to be reliably fit as some of the more complex models. In the
context of our mathematical model, the cells follow a stochastic
process: during each elementary time step, a cell is chosen
proportional to fitness for reproduction, death, or export from
the primary tumor to establish a metastatic colony elsewhere.
Time is measured in numbers of cell divisions.
Cells that have not yet evolved the ability to metastasize are
called type-0 cells (Figure 1B). These cells divide at rate r and
die at rate d per time unit. Initially, we consider metastatic ability
to be a consequence of a single genetic or epigenetic change, for
example the genetic inactivation of SMAD4 (Hahn et al., 1996;
Iacobuzio-Donahue et al., 2009; Nguyen and Massague´, 2007;
Polyak and Weinberg, 2009; Saha et al., 2001; Valastyan et al.,
2009); this assumption will be relaxed in later sections. Such
an (epi)genetic alteration occurs with probability u per cell divi-
sion. Cells carrying the alteration are called type-1 cells. These
cells divide at rate a1 and die at rate b1 per time unit. Once a
type-1 cell has been produced, it has a certain probability of
being exported from the primary tumor to attempt the establish-
ment of metastases elsewhere. The integrated rate of leaving the
primary site and founding a new colony at a distant site is de-
noted by q (Figure 1B). Mutation and dissemination are unlikely
to occur at the same time but instead are likely separated in time.
The relative fitness of type-1 cells as compared to type-0 cells
is given by a1 = ða1  b1  qÞ=ðr  dÞ since an increased rate of
export, q, contributes to the loss of cells from the primary tumor
and hence leads to a selective disadvantage of type-1 cells in
that environment. If a1 = 1, then the fitness of type-1 cells is
neutral as compared to that of type-0 cells and the metastasis-
enabling mutation does not confer an advantage or disadvan-
tage to the cell in the primary tumor. If a1>1 – either through an
increased growth rate or a decreased death rate of type-1 cells,
then these cells have a fitness advantage; and if a1<1 – either
through a decreased growth rate, an increased death rate or a
sufficiently large rate of export of type-1 cells, then they have a
fitness disadvantage as compared to type-0 cells in the primary
tumor. Once a type-1 cell has migrated to a distant site, it initi-
ates exponential growth with division rate a2 and death rate b2
per time unit. The relative fitness of type-2 cells as compared
to type-1 cells is given by a2 = ða2  b2Þ=ða1  b1  qÞ. Again,
if a2 = 1, then the fitness of type-2 cells is neutral, if a2>1, it is
advantageous, and if a2<1, it is disadvantageous as compared
to the fitness of type-1 cells in the primary tumor.
The total number of tumor cells (including all three types) at
diagnosis is denoted byM1, and the total number of tumor cells
at autopsy is given by M2. Here, diagnosis refers to the initiale probability of metastasis at diagnosis. The color represents the deviations
a on the number of metastatic sites and metastatic cells for the estimation, and
s represent the region of fit between theory and data. Panel (D) provides a more
probability of the existence of cells in the primary tumor that have evolved the
10-7, r = a1 = 0.16, a2 = 0.58, d = b1 = 0.01r, and b2 = 0.01a2.
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Table 2. Correlations between Various Measures of Tumor Size and Growth Rate as Well as Survival in the Autopsy Cohort
Primary Size
at Diagnosis
Metastasis Size
at Diagnosis
Primary Size
at Autopsy
Largest Metastasis
at Autopsy
Primary
Growth Rate
Metastasis
Growth Rate
Primary size at diagnosis 1.00
Metastasis size at diagnosis 0.08 1.00
Primary size at autopsy 0.36* 0.10 1.00
Largest metastasis at autopsy 0.01 0.51* 0.01 1.00
Primary growth rate 0.04 0.10 0.28* 0.20* 1.00
Metastasis growth rate 0.03 0.15 0.02 0.07 0.23* 1.00
Survival 0.18 0.45* 0.01 0.14 0.13 0.32*
See also Table S2 and Figure S1. *p < 0.05.detection of the tumor when the patient is first admitted to the
hospital, and autopsy refers to the time of patient death when
the tumor burden is assessed and the cause of death is deter-
mined. We expect that all three cell types contribute to the size
at diagnosis since in rare cases, metastatic disease with
unknown primary is diagnosed, where only type-2 cells can be
detected (Ayoub et al., 1998). Once the tumor has been diag-
nosed with a population size of M1, there are four options in
the mathematical framework, which in the clinic depend on
a host of other factors such as patient age and co-morbidities:
(1) there may be no treatment; (2) the patient may receive
surgery, which removes a fraction ε of the primary tumor; (3)
the patient may undergo chemotherapy or chemoradiation,
which reduces the growth rate of all cells by a factor of g; or (4)
the patient may receive surgery and chemotherapy or
chemoradiation.
This stochastic mathematical model serves to investigate the
probability that metastases are present within a patient at
a particular time during tumorigenesis, the total number of
cancer cells, the effect of chemotherapy or chemoradiation
and resection on these quantities, and the survival time of cancer
patients. Analytic approximations for those quantities are shown
in the Experimental Procedures section. With these quantities,
we then estimated the mutation rate (u) and metastasis rate (q)
by minimizing the deviations between the patient data on the
numbers of metastatic sites and metastatic cells and the
corresponding predictions obtained using the formulas. This
approach could only be performed utilizing the autopsy patient
cohort for whom detailed information of metastatic burden after
death was available. Using these estimates, we then predicted
the risk of metastasis at diagnosis as well as the expected
number and size of metastatic sites and patient survival in both
databases (autopsy and adjuvant cohorts). Finally, we investi-
gated the effects of different treatment modalities on patient
survival.
Growth Kinetics of Primary and Metastatic Tumors
We first investigated the correlations between primary and
metastatic tumor sizes at diagnosis and autopsy as well as their
growth rates utilizing the autopsy patient cohort (Table 2). In
general, primary tumor-related variableswere significantly corre-
lated with each other and metastasis-related variables were sig-
nificantly correlated with each other. Of note, tumor growth was
slower for primary tumors that were larger at diagnosis. This366 Cell 148, 362–375, January 20, 2012 ª2012 Elsevier Inc.effect is not a function of primary tumor removal, as the partial
correlation between growth of the primary and size at diagnosis
was 0.25 (p value = 0.03, partialing out primary removal). In
the adjuvant cohort, all patients underwent surgery so the
corresponding partial correlation could not be estimated, but
the correlation between size at resection and local growth rate
was insignificant (correlation coefficient 0.07, p value = 0.73).
Survival times were calculated from diagnosis to death, and
growth rates of primary and metastatic tumors were computed
using our exponential growth model. For some patients, no
tumor was detected at a given location (primary or metastatic)
at a given time (diagnosis, intermediate evaluations, or autopsy).
We imputed a tumor size of 0.1 cm for those time points, based
on estimates of the minimal size of radiographically detectable
local and metastatic tumors (MSKCC gastroenterologists,
personal communication). This choice was further supported
by the fact that the smallest measured tumor anywhere at any
time point in our data was 0.2 cm. Table 2 and Figure S1A
present the correlations between tumor-related variables and
survival. Both the size of the largest metastasis at diagnosis
and the growth rate of metastatic tumors were significantly
correlated with survival (in each case, p value < 0.05). We also
tested the sensitivity of our results for variations in the assump-
tion of a 0.1 cmdiameter for undetectedmetastases. In Table S2,
we reproduced Table 2 while using 0.2 and 0.05 cm as the mini-
mally detectable tumor sizes with radiographic imaging. Most of
our conclusions remained unchanged, suggesting robustness of
our findings.
We then estimated the model parameters using the autopsy
patient cohort (see Extended Experimental Procedures and
Table S2C). The coefficients in Table S2C are on a multiplicative
scale; for example, surgical removal of the primary almost
doubles predicted survival (e0.632 = 1.88) when growth rates
and size of the largest metastatic tumor at diagnosis were held
constant. One unit increase in either the primary or the meta-
static growth rate (other factors kept constant) decreased pre-
dicted survival by approximately 22%, and one cm increase in
the largest metastatic tumor decreased predicted survival by
32%. All of these factors were significantly associated with
survival. This robust regression model had a good fit (R2 =
0.41, AIC = 102.9) and approximately normally distributed resid-
uals (Figures S1B and S1C).
Because of the multiple combination regimens used in the
autopsy cohort, only limited analyses of treatment effects could
be performed for this database. Forty-one (41%) of the patients
in the autopsy cohort received chemotherapy only, while 45
received both chemotherapy and radiotherapy. Neoadjuvant
therapy was used in only two patients, while the rest of the
treatments in the surgical patients were in the adjuvant setting.
First-line treatment included gemcitabine in 56 of the 86 patients
(65%) who received chemotherapy and 5-FU in 10 patients
(12%).
The adjuvant cohort of patients, in contrast, did contain infor-
mation about the use of chemotherapy following resection. In
this patient cohort, all patients received adjuvant chemotherapy,
with 84% receiving 5-FU based chemoradiation and 16%
gemcitabine-based therapy. There was no difference between
the survival profiles of patients receiving 5-FU or gemcitabine
in the adjuvant setting (p value = 0.68, Wilcoxon test).
The Probability of Metastases at Diagnosis
We then utilized our mathematical framework to estimate the
rate of accumulating one specific (epi)genetic alteration that
enables cells to metastasize (u in our mathematical model) and
the dissemination rate (q) by using information regarding the
numbers of metastatic sites and metastatic cells at autopsy
from the autopsy patient cohort. Figure 1C shows the log-scale
deviations between the data and the predictions of the model
(see Experimental Procedures) for a wide range of values of
the mutation and dissemination rates, u and q. We identified
the region of fit for these rates as 1013 < u q < 109. We then
further investigated the fit between data and theory in this
parameter region (Figure 1D) while using a constraint of the
mutation rate, 108 < u < 104; this choice was made since
experimental evidence suggests that the mutation rate per
base per cell division is about 108 in genetically stable cells and
about 104 in cells with microsatellite instability (Lengauer et al.,
1997, 1998; Seshadri et al., 1987). Values of u = 6.31 $ 10-5 and
q = 6.31 $ 10-7 were identified as the best combination of these
parameters thatminimize the deviations between data and theory
(see Experimental Procedures for details of the parameter
estimation).
Using our mathematical framework together with the esti-
mated rates, we then investigated the probability that metastatic
cells as well as cells with the potential to metastasize are present
at the time of diagnosis (Figure 1E). Of note, we found that all
patients are expected to harbor metastasis-enabled cells in the
primary tumor at the time of diagnosis, even when the size of
the primary tumor is small. Not all patients, however, are
expected to present with metastatic disease at diagnosis
(Figure 1E). A patient with a primary tumor of 1 cm diameter,
for example, has a probability of 28% of harboring metastases
at the time of diagnosis; as the primary size increases to 2 and
3 cm, the risk of harboring metastases becomes 73% and
94%, respectively.
To validate the accuracy of the mathematical framework
and the estimated parameter values, we tested the fit between
the autopsy patient data and our model predictions with regard
to the distribution of survival times, the size of the primary tumor,
and the extent of metastatic disease at autopsy (Figure 2).
We obtained an accurate fit for these quantities, suggesting
that our mathematical framework together with the estimatedmutation and dissemination rates capture the dynamics of
pancreatic tumor growth andmetastasis formation exceptionally
well.
We then sought to further validate our predictions in an inde-
pendent database of pancreatic cancer patients who underwent
curative resection (pancreaticoduodenectomy) and received
adjuvant 5-FU or gemcitabine-based chemoradiation. We first
validated the growth rate estimates obtained from the autopsy
dataset using this adjuvant patient cohort, and observed agree-
ment between the estimates (Figure 3A). We then tested our
predictions of survival times using the adjuvant cohort: we
used the growth kinetics learned from the autopsy database to
predict the distribution of survival times in the adjuvant database
and obtained an excellent fit (Figures 3B–3D). Note that the vari-
ability in the patient data is due to the small number of patients
for whom sufficient data was available (18, 28, and 22 patients
for Figures 3B, 3C, and 3D, respectively).
Treatment Reducing Tumor Cell Proliferation Most
Effectively Prolongs Survival
After validating the accuracy of the mathematical model and the
estimated parameter values in two independent databases, we
utilized our mathematical framework to evaluate the effects of
different treatment options on patient survival. This investigation
was performed using the distributions of tumor sizes at autopsy
and the growth rates of primary and metastatic tumors provided
by the autopsy patient cohort, as well as the estimated mutation
and dissemination rates. These quantities were then used to
predict the effects of therapeutic options on disease outcomes
(Figure 4). We evaluated both resection and chemotherapy strat-
egies for their effectiveness in attenuating tumor progression
and prolonging survival. Interestingly, a reduction in the growth
rate of both primary and metastatic tumor cells was more effi-
cient in extending patient life expectancy than surgical resection
(Figures 4A and 4B, red curves). Surgical resection of the primary
tumor, even if done efficiently such that 99.99% of the primary
tumor was removed (i.e. no macroscopic disease left behind),
led to less promising results (Figures 4A and 4B, blue curves).
This finding indicates that a reduction in the growth rates of
primary and metastatic tumors may be more effective in attenu-
ating tumor growth than upfront surgical resection of the tumor
mass since inevitably, a fraction of cells will remain and lead to
exponential expansion of the tumor while the patient is recov-
ering from surgery (average 4–12 weeks). As expected, thera-
peutic interventions that are initiated as soon as possible after
diagnosis, and diagnostic tools that lead to earlier discovery of
the tumor, are more effective than interventions that commence
at a later time. Moreover, we investigated the effects of different
treatment strategies on the number of metastatic sites at
autopsy, the number of primary tumor cells, the number of meta-
static tumor cells, and the number of metastatic tumor cells per
site (Figures 4C–4J). The expected number of metastatic sites at
autopsy increases with the administration of chemotherapy and
decreases with resection, because slow tumor growth caused
by drug therapy enhances the chance of metastatic events while
resection decreases the number of primary tumor cells, which
are the underlying cause of metastatic events (Figures 4C and
4D). Surgical resection decreases the number of primary tumorCell 148, 362–375, January 20, 2012 ª2012 Elsevier Inc. 367
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Figure 2. The Predictions of the Mathematical
Framework Are Validated Using Patient Data
(A and B) The panels show the distribution of survival times
of patients who were diagnosed with primary tumors with
a diameter of 2.5 - 3.4 cm (A) and of 3.5 – 4.4 cm (B).
(C and D) The panels show the distribution of the number
of metastatic cells at autopsy of patients who were diag-
nosed with primary tumors with a diameter of 2.5 - 3.4 cm
(C) and of 3.5 - 4.4 cm (D).
(E and F) The panels show the distribution of the number of
primary tumor cells at autopsy of patients who were
diagnosed with primary tumors with a diameter of 2.5–
3.4 cm (E) and of 3.5–4.4 cm (F).
In all panels, the red curves represent the prediction of the
mathematical framework and the black lines represent
the data. We observed no significant difference between
the predictions and the data; the p values are (A) 0.26, (B)
0.63, (C) 0.54, (D) 0.47, (E) 0.13, and (F) 0.11. Parameters
are u = 6.31 $ 10-5, q = 6.31 $ 10-7, d = b1 = 0.01r, b2 =
0.01a2 and g = 0.7. Tumor size at autopsy was obtained
from the normal distribution with mean 11.2 and variance
0.46 in a base 10 logarithmic scale for each calculation.
The growth rate of primary tumor cells and metastatic
tumor cells are obtained from the normal distribution with
mean 0.16 and variance 0.14, and mean 0.58 and variance
2.72, respectively.cells at autopsy (Figures 4E and 4F). The number of metastatic
cells at autopsy does not vary with different treatment options
(Figures 4G and 4H), implying that the number of metastatic cells
is generally the determinant of death. Patients who receive
chemotherapy tend to harbor smaller metastatic sites and those
who receive tumor resection have large metastatic sites (Figures
4I and 4J).
Figure 5 displays the effects of treatment delays both on the
tumor volume and patient survival for a set of theoretical thera-
peutic interventions (see Experimental Procedures for details
of the calculations). We found that early initiation of treatment
effectively prolongs survival and that any treatment delay leads
to a worse prognosis than earlier initiation of therapy, indicating
that immediate suppression of tumor growth is essential for
patient survival.
Additional Factors Related to Patient Outcome
We then estimated the cross-correlations of all clinical variables
in the adjuvant patient cohort. There were significant correlations368 Cell 148, 362–375, January 20, 2012 ª2012 Elsevier Inc.between the following pairs of variables: CAD
and MI (correlation = 0.56, p < 0.001), CAD
and HTN (0.29, 0.001), CAD and grade (0,23,
0.008) and PNI and grade (0.19, 0.032); these
findings are in line with previously published
results.
Finally, we identified important indices that
forecast the prognosis of patients with statistical
significance (Table S1B). As expected, tumor
pathological grade was found to be a significant
indicator of prognosis (p value = 0.014). More-
over, we found that a high concentration of the
tumor marker CA 19-9 before surgery (p value =0.005) and after surgery (p value = 0.001) significantly indicates
poor prognosis. None of the other correlations were significant.
Alternative Model Assumptions
To investigate the robustness of our findings to the assumption
that a single (epi)genetic alteration is sufficient to confer meta-
static ability to pancreatic cancer cells, we designed an alterna-
tive mathematical framework in which two alterations are
necessary to gain such ability (Supplemental Information). The
model considers exponential expansion of pancreatic cancer
cells starting from a single cell that has not yet evolved the ability
to metastasize. Again, the cells follow a stochastic process:
during each elementary time step, a cell is chosen proportional
to fitness for reproduction, death, or export from the primary
tumor to establish a metastatic colony elsewhere. Cells that
have not yet acquired the ability to metastasize are called
type-s0 cells and accumulate the first alteration toward the
metastatic phenotype with probability v1 per cell division. Cells
carrying this alteration are called type-s1 cells and accumulate
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Figure 3. Validation of Our Framework Using an Independent Patient Cohort
(A) The distribution of the primary growth rate from the original dataset including 101 patients is shown in blue and that from the additional data in black; for the
latter, only 10 patients had sufficient follow-up measurements (size at diagnosis, intermediate, and death) such that the growth rate could be determined.
(B) The panel shows the distribution of survival times of patients after resection of the primary tumor with 2 (1.5–2.4) cm diameter after diagnosis. The red curve
represents the prediction of the mathematical framework and the black line represents the data.
(C) The panel shows the distribution of survival times of patients after resection of the primary tumor with 3 (2.5–3.4) cm diameter after diagnosis. The red curve
represents the prediction of the mathematical framework and the black line represents the data.
(D) The panel shows the distribution of survival times of patients after resection of the primary tumor with 4 (3.5–4.4) cm diameter after diagnosis. The red curve
represents the prediction of the mathematical framework and the black line represents the data. We observed no significant difference between the predictions
and the data; the p values are (A) 0.45, (B) 0.44, (C) 0.40, and (D) 0.41. Parameters used are u = 6.31 $ 10-5, q = 6.31 $ 10-7, d = b1 = 0.01r, b2 = 0.01a2 and g = 0.7.
Tumor sizewasobtained fromanormal distributionwithmean 11.2 and variance 0.46 in a base 10 logarithmic scale for each calculation. Thegrowth rate of primary
tumor cells andmetastatic tumor cells were obtained from a normal distribution withmean 0.16 and variance 0.14, andmean 0.58 and variance 2.72, respectively.
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Figure 4. The Mathematical Framework Predicts Optimum Treatment Strategies for Pancreatic Cancer Patients
The panels show the predictions of different quantities for a tumor size of 1 cm diameter at diagnosis (left column) and 3 cm at diagnosis (right column). The tumor
size at autopsy in a 10 base logarithmic scale was obtained from a normal distribution with mean 11.2 and variance 0.46 for each calculation. The growth rates of
primary tumor cells and metastatic tumor cells were obtained from a normal distribution with mean 0.16 and variance 0.14; and mean 0.58 and variance 2.72,
respectively. The black curve represents mathematical predictions of the survival time without treatment or resection, the blue curve with resection (removal of
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AB
C
Figure 5. A Delay in the Initiation of Therapy Signif-
icantly Increases Tumor Volume and Shortens
Survival
The panels show the prognosis after surgery with
different theoretical treatment options and treatment
delays. Panel (A) shows the median of the number of
tumor cells in 100 trials over time. Panel (B) shows the
fraction of surviving patients in 100 trials at each time
point. Panel (C) shows the numbers of tumor cells and the
fraction of surviving patients. The tumor size at autopsy
was obtained from a normal distribution with mean 11.2
and variance 0.46 in a 10 base logarithmic scale. The
growth rates of primary tumor cells and metastatic tumor
cells were obtained from a normal distribution with mean
0.16 and variance 0.14; and mean 0.58 and variance
2.72, respectively. The black curve represents the case
with no treatment after surgery, the red curve with starting
treatment immediately after surgery, and the green, blue,
and yellow curves with starting treatment 2, 4, and
8 weeks after surgery, respectively. Parameters are u =
6.31 $ 10-5, q = 6.31 $ 10-7, d = b1 = 0.01r, b2 = 0.01a2, ε =
0.9999, and g = 0.7.the second alteration toward the metastatic phenotype with
probability v2 per cell division. Cells carrying two (epi)genetic
alterations are called type-s2 cells and may be exported from
the primary tumor to attempt the establishment of metastases
elsewhere at rate q. Once disseminated, the cells are called
type-s3 cells. Type-s0, -s1, -s2, and -s3 cells divide at rates r,
s1, s2, and s3 while they die at rates d, d1, d2, and d3, respec-
tively, per time unit. This model was used to investigate the
dynamics of growth, dissemination, and treatment response of
pancreatic cancer patients, both for genetically stable cells as
well as tumors with genomic instability (Figure S2, Figure S3,
Figure S4, Figure S5, Figure S6, and Figure S7). Although we
were unable to estimate both mutation rates as well as the99.99% of the primary tumor by surgery), the red and green curves with treatment (90% [red] and 50%
resection and treatment (removal of 99.99%of the primary tumor by surgery and 90% reduction of the
d= b1 = 0.01r, b2 = 0.01a2, ε= 0.9999, and g = 0.9 (red and purple curve) and g= 0.5 (green curve). (A an
at autopsy. (E and F) The number of primary tumor cells. (G and H) The number of metastatic tumor c
See also Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, and Figure S7.
Cell 148, 36dissemination rate from patient data, the main
predictions of our framework remained consis-
tent with this alternative modeling assumption
(Figure S2, Figure S3, Figure S4, Figure S5, Fig-
ure S6, and Figure S7). For instance, we again
found that a reduction of the growth rate is
more effective for prolonging patient survival
than surgical removal of the primary tumor (Fig-
ure S2). Our conclusions are thus robust to the
choice of the modeling framework to investigate
pancreatic cancer growth and dissemination.
DISCUSSION
Computational modeling applied to well-anno-
tated data derived from a large series of patients
provides the unique opportunity to dissect thegrowth and dissemination dynamics of pancreatic cancer
metastases. This approach indicated only a weak relationship
between the growth characteristics of primary pancreatic
cancers and their matchedmetastases. Of note, this observation
is not simply explained by differences in therapeutic manage-
ment, and is evidenced by large primary tumors (pT4 stage)
without metastases at autopsy despite a long overall survival,
and small primary carcinomas (pT1 stage) with concurrent wide-
spread metastatic disease (Table S2C). Differences in growth
kinetics of the primary and metastatic sites may be accounted
for by inherent differences in the microenvironment (Nguyen
et al., 2009; Talmadge and Fidler, 2010), by the extent of hypoxia
(Lu and Kang, 2010), or by differences in the epigenetic or[green] reduction of the growth rate), and purple curve with
growth rate). Parameters are u = 6.31 $ 10-5, q = 6.31 $ 10-7,
d B) Survival time. (C andD) The number ofmetastatic sites
ells. (I and J) The number of metastatic tumor cells per site.
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genetic features of the subclonal populations that gave rise to
the distant metastases (Campbell et al., 2010; Yachida et al.,
2010). These questions provide fertile ground for additional
studies.
The biggest implication of this model is its predictions for
timing of and type of clinical intervention that most effectively
impact survival. For example, when investigating the correlation
between the tumor-related variables and the survival time of
patients (Table 2 and Figure S1A), we found that both pancreatic
tumor size at diagnosis/resection and growth rate of a pancreatic
tumor shorten the patient’s survival. We then estimated the
rate of acquiring an (epi)genetic alteration that confers meta-
static ability to tumor cells, u, and the dissemination rate of
such cells, q, to be u = 6.31 $ 10-5 per allele per cell division
and q = 6.31 $ 10-7 per time unit. The patient data, together
with these rate estimates, were then used to predict the proba-
bility of metastatic disease at diagnosis, the number and size
distribution of metastatic tumors, and the effects of particular
treatment strategies on tumor volume and patient survival.
Overall, our predictions suggest that chemotherapeutic agents
capable of effectively reducing the growth rate of primary and
metastatic tumors are most promising for prolonging survival
of pancreatic cancer patients as compared to surgery alone.
These predictions are testable in the laboratory and the clinic.
Moreover, since our model predicts that most patients have
metastatic disease at the time of diagnosis, upfront surgery
which only influences local tumor progression is less effective
than chemotherapy which can affect both local and distant
tumor progression (Amikura et al., 1995; Yachida et al., 2010).
Further, our model suggest that surgery serves only to debulk
the overall tumor cell burden but does not fully eradicate it. By
extension, this prediction also infers that earlier initiation of effec-
tive chemotherapeutic agents has a survival benefit by reducing
the number of cells in the exponential growth stage (Figure 5),
a finding of tremendous clinical significance in light of the
ongoing debates regarding neoadjuvant versus adjuvant treat-
ment of resected pancreatic cancers (Hsu et al., 2010; Katz
et al., 2009). Adjuvant chemotherapy and radiation after surgery
has been shown to promote longer overall survival compared
to patients who undergo surgery alone (Hsu et al., 2010). Of
interest, recent data indicates that neoadjuvant therapy is
associated with an even longer overall survival compared to
adjuvant therapy in patients with resectable pancreatic cancer,
in keeping with this possibility (Artinyan et al., 2011). The addition
of neoadjuvant radiation therapy may slow tumor proliferation
and prevent further metastases, while adjuvant radiation therapy
may promote eradication of residual microscopic disease
following surgery. However, our data suggests that aggressive
full-dose systemic therapy is needed to suppress tumor prolifer-
ation. Therefore, if radiation therapy is used in the neoadjuvant/
adjuvant setting, it should be delivered with full-dose aggressive
chemotherapy (if possible) or the duration of radiation therapy
needs to be minimized (stereotactic radiation) to allow for con-
tinuous chemotherapy treatment in order to suppress tumor
proliferation (Desai et al., 2009; Schellenberg et al., 2011).
In our statistical analyses, we did not consider a death bias
because pancreatic cancer patients have a short expected
survival time and are therefore unlikely to die from other372 Cell 148, 362–375, January 20, 2012 ª2012 Elsevier Inc.causes. We also did not consider an autopsy consent bias
since we did not find any evidence that patients who consented
to a rapid biopsy had different characteristics than those who
did not. Furthermore, in the autopsy database, we did not
observe a significant difference in growth rates of tumors
between patients that did and did not receive chemotherapy;
this effect is likely due to the modest efficacy of currently avail-
able treatments (Neoptolemos et al., 2004; Neuhaus et al.,
2008; Oettle et al., 2007) although it conceivably also stems
from the small size of the autopsy cohort as well as the small
number of patients receiving the same therapy. In the mathe-
matical framework, we considered a common growth rate for
all cells in the primary tumor – both cells that have not yet accu-
mulated the alteration(s) conferring metastatic ability to cells,
and metastases-enabled cells. The latter cells may have
a different growth rate, which was not considered in the
present study for clarity. Since detailed knowledge of these
parameters is important for the determination of the accurate
mathematical formulation and thus the dynamics of metastasis
and identification of optimum treatment strategies, it is an
important goal of the field to obtain these values from detailed
kinetic studies of cancer cells. Finally, although the primary
tumor sizes were obtained by pathology in the autopsy cohort
and by imaging in the adjuvant cohort, we are confident that
the values are comparable since based on data from our
group and others (Arvold et al., 2011), the maximum tumor
size on preoperative imaging is on average within 0–5 mm of
the pathologic tumor size (Qui et al., unpublished data).
Our work highlights the utility of a unique mathematical frame-
work revealing the complex dynamics of the metastatic dissem-
ination of pancreatic cancer cells and suggests that aggressive
systemic therapy should be offered early after diagnosis regard-
less of the stage of the disease. Our findings also have implica-
tions for the investigation of other cancer types for which similar
data can be obtained.
EXPERIMENTAL PROCEDURES
Mathematical Expressions of Metastatic Properties
In order to estimate the metastatic mutation rate (u) and metastasis rate (q),
we examined the deviations between the data of metastatic sites and meta-
static cells and the predictions of our mathematical model. We used the
data of the number of metastatic sites and metastatic cells from 23 patients
whose tumors were not resected after diagnosis, who were treated with
chemotherapy, and who had positive net growth rates. The formula for the
expected number of metastatic sites is given by
E =
XM11
i = 1
½Aði; tiÞðDi  Di + 1Þ+E0 +G$E1:
The first term on the right-hand side of the equation represents the expected
number of newmetastatic sites after diagnosis for the case in which type-1 cells
exist at diagnosis. The second term represents the expected number of meta-
static sites before diagnosis, and the third term denotes the expected number
of newmetastatic sitesafterdiagnosiswhennomutationsoccurbeforediagnosis.
Here
Di =1 exp


Z kihi
0
rueðrð1uÞdÞv

1 b1 +q
a1

dv

:
We further have hi = In i=ða1  b1  qÞ and ki = In ðM1  iÞ=ðrð1 uÞ  dÞ, as
well as
Aði; tiÞ=
Z ti
0
qyaðkÞ

1 b2=a02

dk
=
ya

0

q

eða01b1qÞti  11 b2=a02
a01  b1  q
+
r0uqxa

0

1 b2=a02

r 0ð1 uÞ  d  a01 +b1 +q

eðr
0 ð1uÞdÞti  1
r 0ð1 uÞ  d 
eða01b1qÞti  1
a01  b1  q

where r 0 = rð1 gÞ; a01 = a1ð1 gÞ; a02 = a2ð1 gÞ, and
G= exp

 M1u
1 d=r
Z 1
0
1 ðb1 +qÞ=a1
1 ½ðb1 +qÞ=a1va1 dv

;
where a1 = ða1  b1  qÞ=ðr  dÞ.
Here, xaðtÞ= ðM1  iÞð1 εÞeðr0 ð1uÞdÞt and
ya

t

= ið1 εÞeða1b1qÞt
+
ðM1  iÞð1 εÞr 0u
r 0ð1 uÞ  d  a01 +b1 +q

eðr
0 ð1uÞdÞt  eða01b1qÞt

:
The effects of resection and chemotherapy are denoted by ε and g,
respectively. The expression ti is obtained from ðM1  iÞð1 εÞeðr0dÞti +
ið1 εÞeða01b1qÞti = M2.
The expected number of new metastatic sites after diagnosis for the case
in which no mutations occur before diagnosis is given by
E1 =
XM21
x =M1ð1εÞ
ebðx1Þ

1 ebqeða01b1qÞt0x

1 b2=a02

ða01  b1  qÞ

:
The expression t0x in the equation is obtained from xe
ðr0dÞt0x +
eða
0
1
b1qÞt0x =M2.
The formula for the expected number of metastatic cells is given by
Z =
XM1 = 1
x = 1
pðxÞ
Z tx
0
LðsÞzaðt0Þds
+
XM11
x =1
pðxÞ exp


Z tx
0
qeða1b1qÞv

1 b2
a2

dv
 Z t0x
0
L0ðt0Þeða02b2Þk0x;t0 dt0;
where pðxÞ= eðx1Þbð1 ebÞ,
LðsÞ= exp
eða1b1qÞs  1q
a1  b1  q

1 b2
a2
 
1 exp

 qeða1b1qÞs

1 b2
a2
!
;
and
L0ðt0Þ= exp
"

Z t0
0
qy0e
ða01b1qÞv

1 b2
a02

dv
#
3

1 exp

 qy0eða01b1qÞt0

1 b2
a02

:
The expressions t0, t0x , and k
0
x;t0 are respectively obtained from x0e
ðr0dÞt0 +
y0e
ða0
1
b1qÞt0 + z0eða
0
2
b2Þt0 =M2, x0eðr
0dÞt0x + y0eða
0
1
b1qÞt0x =M2, and
x0e
ðr0dÞðt0 + k0
x;t0 Þ + y0e
ða0
1
b1qÞðt0 + k0x;t0 Þ + eða
0
2
b2Þk0x;t0 =M2. Moreover, x0 = ð1 εÞ
xeðrdÞðs+ kx;sÞ, y0 = ð1 εÞeða1b1qÞðs+ kx;sÞ, and z0 =eða2b2Þkx;s , and kx;s is ob-
tained from xeðrdÞðs+ kx;sÞ + eða1b1qÞðs+ kx;sÞ + eða2b2Þkx;s =M1. The expression
za is given by the differential equation dza=dt = ða02  b2Þza with the initial
condition, zað0Þ= eða2b2Þkx;s . Here the number of primary tumor cells at autopsy
is given by M2  Z. For more details, see (Haeno and Michor, 2011).
Estimation of Mutation and Dissemination Rates
The deviations between the data and formula are calculated by the following
equation:
Dev =
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃY ln½ith data of the number of metastatic sites or cells
ln½predictionðu;q;g; r ; a ; a ;d ;b ;b ;M ;M Þ
2
i
vuut :
i
i 1i 2i i 1i 2i 1i 2iHere i is an index enumerating the patient data. In this analysis, we assumed
that the net growth rates of type-0 cells and type-1 cells were the same, death
rates of tumor cells (d, b1, b2,) were 100 times lower than division rate (r, a1, a2,),
and the reduction of growth rate by chemotherapy (g) was zero. We examined
different values of the reduction of growth rates by chemotherapy and death
rates and found little effect of such changes on the estimated regions of muta-
tion and metastatic rates. The number of tumor cells in 1 cm3 tumor bulk is
considered to be a billion.
Reproduction of Distributions of Survival Time and Metastatic Cells
For this analysis, we used estimated parameters of the net growth rate of the
primary tumor (0.16 per month with variance 0.46) and metastases (0.58 per
month with variance 2.72), mutation rate (u = 6.31 $ 10-5), and dissemination
rate (q = 6.31 $ 10-7). The growth rates of primary and metastatic tumor cells
with variance were obtained from the time series data of tumor size for all
patients. We obtained the distribution of the total tumor cells in a base 10 log-
arithmic scale at autopsy as a normal distribution with mean 11.2 and variance
0.46 from the autopsy cohort. In the mathematical calculation, the number of
tumor cells at autopsy followed this distribution. To obtain the survival time
after diagnosis, we first consider the expected number of metastatic cells at
diagnosis, given by
Zd =
XM11
x =1
PðxÞ
Z tx
0
LðsÞeða2b2Þkx;sds:
Then the survival time is given by
ðM1  ZdÞeðr0dÞts +Zdeða02b2Þts =M2:
For more details, see (Haeno and Michor, 2011).
The Effects of a Delay in the Initiation of Therapy
We considered 100 cases in the mathematical model described above and for
each case in which a patient develops a 3 cm tumor at diagnosis, we utilized
the estimated mutation and metastatic rates as well as different primary and
metastatic growth rates that follow normal distributions with the estimated
mean and variance. Surgery removes 99.99% of primary tumor cells at time
0. We tested five scenarios: (1) no treatment after surgery, (2) starting treat-
ment immediately after surgery, (3) starting treatment 2 weeks after surgery,
(4) starting treatment 4 weeks after surgery, and (5) starting treatment 8 weeks
after surgery. Treatment reduces the growth rate of tumor cells by 70% in this
analysis, which is derived from the validation of the model (Figure 2 and Fig-
ure 3). The number of tumor cells at death follows a normal distribution with
mean 11.2 and variance 0.46 in a base 10 logarithmic scale. Survival time after
surgery, ts, is obtained from
ðM1  ZdÞeðrdÞtj eðr0dÞðtstjÞ +Zdeða2b2Þtj eða02b2ÞðtstjÞ =M2;
where treatment starts at time tj. The first term on the left-hand side represents
the number of primary tumors and the second term represents the number of
metastatic tumor cells after surgery.
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